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ABSTRACT
Objective: To investigate healthcare experiences of
patients with age-related macular degeneration (AMD)
and determine whether a previous survey and Royal
College of Ophthalmologists (RCOphth) management
guidelines brought improvements.
Design: Cross-sectional survey of Macular Society
members in 2013 compared with previous 1999
survey.
Setting: UK Postal Questionnaires.
Participants: 1169 respondents in 2013 (1187 in
1999).
Intervention: Publication of 1999 survey results
(2002), and RCOphth AMD guidelines (2009).
Main outcome measures: Respondents answered
questions about experiences at diagnosis. Five
questions were replicated from the 1999 survey for
direct comparison in the 2013 survey which included
additional questions based on 2009 RCOphth
recommendations for information and support
provision for patients with AMD.
Results: Most 2013 survey respondents were given
the name of their macular condition (91%), felt the
healthcare professional was interested in them (71%)
and were satisfied overall with the diagnostic
consultation (76%). These outcomes show significant
improvement since 1999. Within the 2013 sample,
multivariable analyses showed gradual trends of
improvement over time in: provision of written
information, Macular Society information and receiving
appropriate help, support and advice at diagnosis.
Only overall satisfaction with the diagnostic
consultation (but not the other nine areas of
information and support provision studied)
significantly improved in the time after publication of
the RCOphth 2009 guidelines. There were no
significant improvements associated with the
publication of the 1999 survey results. Low
information and support provision remained, for
example, 44% of respondents diagnosed after the
RCOphth 2009 guidelines reported not receiving
information on what to do if vision deteriorated. Lack
of such information at diagnosis was significantly
associated with registration as sight impaired
(p<0.01). Reports of general practitioner (GP)
knowledge of AMD remained low: 39% reported their
GP was ‘not at all well informed’. The 2013
respondents reported lower levels of help and support
from GPs than 1999 respondents (p<0.001).
Conclusions: Patients diagnosed with AMD after
1999 (vs before 1999) reported better experiences at
diagnostic consultation. However, information and
support provision at diagnosis, and satisfaction with
GPs remained low.
Strengths and limitations of this study
▪ This is the first large-scale, nationwide survey to
examine whether there were changes in health-
care satisfaction following interventions designed
to improve experiences of patients with
age-related macular degeneration. It is also
unique in examining whether respondents felt
they were receiving appropriate support for AMD
from their general practitioners.
▪ The results are timely given that there are
increasing numbers of people diagnosed with
AMD in line with an ageing population.
▪ The main analysis adjusted for differences in
sociodemographic and eye-related factors (eg,
registration status).
▪ Respondents were members of the Macular
Society whose healthcare experiences may not
be representative of the general AMD population.
▪ The survey asked respondents to reflect on their
experiences at the time of diagnosis. It is pos-
sible that recall bias could affect responses.
Literature on autobiographical memory suggests
that women recall more details of events than
men. In this study, however, men were more
likely to report receiving several aspects of infor-
mation and support provision than women. This
suggests that difficulties with recall were not the
main problem here, but rather women were less
likely to be given information and support than
men.
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INTRODUCTION
Age-related macular degeneration (AMD) is a progres-
sive chronic eye condition affecting people aged 50 years
and above.1 AMD may be asymptomatic in the early
stages, but results in vision loss in the late stages of geo-
graphic atrophy (dry AMD) or neovascular (wet) AMD.
Dry AMD can convert to, or be associated with, wet
AMD in the same or contralateral eye. AMD is the
leading cause of blindness in developed countries.2
There were ∼513 000 people living with late AMD in the
UK in 2012, and numbers are expected to grow by a
third by 2020 with the increasing age of the population.3
There are no proven treatments for dry AMD to date
although progression may be reduced with the
Age-Related Eye Disease Study 2 (AREDS 2)formula
nutritional supplements.4 5 Signiﬁcant advances have
been made in treatment for wet AMD with intravitreal
injections of anti-VEGF drugs. Ranibizumab (Lucentis,
Genentech/Novartis) was approved for use in the UK by
the National Institute for Health and Care Excellence
(NICE) in August 2008,6 and has been successful in pre-
venting vision loss.7–10 More recently, aﬂibercept (Eylea,
Regeneron/Bayer) was approved by NICE in July 2013.11
In addition, the off-license use of bevacizumab (Avastin,
Roche/Genentech) has been advocated by some specia-
lists for the same indication since 200612 and has been
found to have similar efﬁcacy to ranibizumab.13
In 1999, a nationwide survey was sent to members of
the Macular Disease Society (now the Macular Society),
a British charitable organisation supporting people with
a macular condition. The results of the survey appeared
in the British Journal of Ophthalmology.14 The Macular
Disease Society Questionnaire (henceforth referred to as
‘MDSQ 1999’) used in the survey was designed in
response to reports of unsatisfactory healthcare experi-
ences from members of a local group of the Society. Key
ﬁndings from the survey included: over 50% of respon-
dents thought that the eye specialist who ﬁrst diagnosed
their macular condition was not interested in them as a
person, and 41% reported being dissatisﬁed with the
diagnostic consultation. Respondents were asked to give
their reasons for dissatisfaction. The most common
reason was the attitude of the eye specialists; they were
commonly seen as being dismissive, patronising, brusque
or unfeeling. The second most cited reason for dissatis-
faction was the lack of information provision to patients
about their condition and/ or what further help was
available. Experiences with general practitioners (GPs)
were not much better. Twice as many respondents
reported that their GP was ‘not at all well informed’
about their macular condition compared with those who
said their GP was ‘very well informed’. About equal
numbers reported that their GP was ‘very helpful and
supportive’ about their macular condition, or ‘not at all
helpful and supportive’.
The Royal College of Ophthalmologists (RCOphth)
subsequently produced guidelines for AMD. Initial guid-
ance focused on possible treatment options12 15 but
guidelines ﬁrst published in February 20091 (updated
September 201316) set standards for best practice and
included recommendations about information to be
communicated to patients within the diagnostic consult-
ation. The guidelines stated that all patients require: a
clear diagnosis (ensuring patients know the name of
their condition), the prognosis and what to do if vision
deteriorates, written information for patient and rela-
tives and signposting to other organisations such as the
Macular Society for further help and support. The
guidelines also highlighted the importance of an aware-
ness of the impact of a diagnosis of this progressive eye
condition, and the need to show empathy with patients.
Moreover, the guidelines emphasised that patients
require information about the possibility of experiencing
visual hallucinations (Charles Bonnet Syndrome (CBS))
in order to avoid distress resulting from incorrectly
attributing the cause of these hallucinations, for
example, to dementia.
A second large-scale nationwide survey was funded by
the Macular Society in 2013 in order to establish if
healthcare experiences had changed for people diag-
nosed with AMD since the 1999 survey. We investigated
whether signiﬁcant improvements had been made since
publication of the 1999 survey results in 2002, and/or
the RCOphth AMD guidelines in 2009.
METHODS
Participants
A total of 4000 members of the Macular Society who
joined after 1 January 2000 were selected from the mem-
bership database using campaign management software
(NFP CARE, Advance Computer Software Group). In
order to achieve an adequate sample size to investigate
the impact of the RCOphth guidelines, we stratiﬁed the
sampling, based on date of joining the Macular Society
(as a proxy for date of diagnosis). Two thousand of the
total 4000 members sampled were randomly selected
from a total sample of 4879 members who had joined
within 3 years prior to the 2013 survey being undertaken
(ie, between 1 October 2010 and 30 September 2013)
(referred to as ‘recently joined’). A further 2000
members were randomly selected from the 7845
members who had joined the Society between 1 January
2000 and 30 September 2010. Further selection criteria
and the number of respondents included/excluded are
summarised in ﬁgure 1.
The MDSQ 1999 (following pilot testing and clariﬁca-
tion as required) was sent to 2000 randomly selected
members of the Macular Society in 1999 and 1421 com-
pleted surveys were received (71% response rate). The
Macular Society has since sent other surveys to its
members, and response rates have fallen (eg, Cox and
ffytche, 2014,17 obtained a response rate of 31%,
n=1254). A total of four thousand 2013 surveys were
mailed in order to achieve a comparable sample size
with the MDSQ 1999.
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Materials
Three key questions on experiences in the diagnostic
consultation from the MDSQ 1999 were replicated to
enable comparison over time. Seven new questions were
designed to assess the incorporation of the RCOphth
guidelines into practice, and focus on information and
support provision around the time of diagnosis.
Sociodemographic information (age, gender) was col-
lected. Eye-related information (wet or dry AMD, regis-
tration status, AMD in one or both eyes and date of ﬁrst
diagnosis) was also gathered together with information
about which healthcare professional (HCP) the respond-
ent considered as the ﬁrst to diagnose their macular
condition. The wording of the questions replicated from
the 1999 survey was modiﬁed as needed to allow for the
more recent development whereby optometrists are now
allowed to diagnose AMD whereas in 1999 only ophthal-
mologists were entitled to give people a diagnosis of
AMD.
Two questions on experiences with GPs were repli-
cated from the 1999 survey. Responses were made on a
Likert Scale of 0 (not at all) to 3 (very). In the 1999
survey, missing data on responses to the two GP ques-
tions were considerable. Many wrote on the survey that
they had not seen their GP about their macular condi-
tion.14 A ‘not applicable’ option was therefore added in
the 2013 survey to investigate how many had not visited
their GP about their AMD.
Similar to the MDSQ 1999, the Macular Society
Questionnaire 2013 (MSQ 2013) was designed for self-
completion by people with a macular condition and
pilot tested.14 Telephone interviews were offered for
both surveys if needed.
Procedure
The Macular Society sent the postal surveys to members
in November 2013. Both 1999 and 2013 surveys provided
free-post return envelopes. Adverts informing members
that the surveys would be sent to randomly selected
members of the Macular Society appeared in SideView
(the membership magazine). No reminders were sent
out to maintain members’ conﬁdentiality.
Twenty six respondents requested telephone survey
completion: all were conducted by EB.
Analysis
To explore the impact of the RCOphth guidelines pub-
lished in February 2009, and the publication of the
MDSQ 1999 results in July 2002, a new variable was
created based on the 2013 survey respondents’ date of
diagnosis (before or after each of these dates). We
explored sociodemographic differences between these
three groups within the 2013 survey data and between
the 1999 and 2013 samples, using Pearson χ2 analyses,
one-way independent ANOVA’S or t-tests (or the non-
parametric equivalent, Mann-Whitney test, where
Figure 1 Flow chart of respondents included in the analyses.
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required). Signiﬁcant results were followed up with post
hoc evaluation of results (eg, examining adjusted resi-
duals for χ2 analyses). Effect sizes are reported for sig-
niﬁcant results.
The outcome variables of interest were the 10 ques-
tions (three replicated and seven new) on healthcare
experiences relating to the diagnostic consultation (eg,
‘Overall, did you feel that the diagnostic consultation
with this HCP was satisfactory?’). Responses were always
binary (‘yes’/‘no’). First we explored differences on
these outcomes using χ2 analyses; between the 1999 and
2013 samples (for the three replicated questions) and
across the three subgroups within the 2013 survey
sample (for all 10 questions). Then binary logistic
regressions were used to assess factors associated
with satisfactory healthcare experiences. Separate
logistic regressions were carried out for each
healthcare-experience question. Independent variables
were the sociodemographic data, information on the
respondent’s eye condition and the main variable of
interest—the survey groups (1999 vs 2013 samples for
the three replicated questions, or the three subgroups of
the 2013 survey sample for all 10 questions). Separate
unadjusted logistic regressions explored the relationship
between each predictor and the outcomes; then multi-
variable analyses with all predictors entered were con-
ducted. The sample size fulﬁlled the requirement of >10
respondents for the lesser reported outcome event (ie,
satisfaction or dissatisfaction) per predictor variable for
multivariable logistic regression analyses (ie, events per
predictor variable).18
Preliminary analyses indicated a general trend of
increasing satisfaction with healthcare experiences over
time. In order to assess the impact of the interventions,
we controlled for this increasing trend by creating a con-
tinuous variable that ranked the respondents’ year of
diagnosis (eg, the ﬁrst year of diagnosis in the data set
was 1980 and was coded as 1, and the last was 2013 and
coded as 30). This variable was entered into the logistic
regression analyses.
No problems with multicollinearity or linearity of the
logit were observed.
Mann-Whitney tests explored differences in experi-
ences with GPs between the 1999 and 2013 sample
groups.
All analyses were conducted in SPSS V.21.0.
Missing data and variables
In the 1999 survey, 709 respondents (58%) had missing
data on whether they had wet or dry AMD. There were
no questions with responses that correlated highly with
this variable from the 1999 survey, so these data were
not imputed, and this variable was not used as a pre-
dictor in the analyses comparing the 1999 and 2013
survey responses. Additionally, there was no question in
the 1999 MDSQ on which HCP had ﬁrst diagnosed
the AMD, so this variable was not entered into analyses
comparing the 1999 and 2013 samples.
There was a total of 289 respondents from the 1999
and 2013 surveys with missing data for age at ﬁrst diag-
nosis (10.3%). The analyses reported here focus on
AMD and so only those who were over the age of 50 at
diagnosis and who had a diagnosis of AMD were
included. Figure 1 explains how missing data were
imputed to aid sample selection.
There were varying amounts of missing data on other
independent variables, the greatest being for date of
diagnosis (missing n=300, 11.4%). There were no suit-
able variables to allow imputation of these missing
values. Analyses reported here comparing the 1999 and
2013 datasets are for those respondents with complete
data on all independent variables included in the ana-
lysis: 1187 from the 1999-survey respondents and 1169
from the 2013 survey. Additional independent variables
were entered into the 2013 survey-only analyses (some
with missing data), and this left 1118 respondents. Item
non-response was <5%. Sample size for each analysis will
vary slightly depending on item non-response.
RESULTS
Sample characteristics
Completed surveys were returned by 1545 respondents
out of the 4000. Telephone completions by 26 gave a
total sample size of 1571 for the 2013 sample (a 39%
response rate). A further 267 uncompleted surveys were
returned, with reasons for non-completion, giving a
gross response rate of 46%. The most common reason
given for non-completion was ‘old age’, followed by ‘ill
health’. The MDSQ 1999 had been completed and
returned by 1421 participants, including four telephone
interviews (71% response rate).
For characteristics of the 1999 and 2013 survey
samples, see table 1. Respondents to the 2013 survey
were signiﬁcantly older and less likely to be registered as
either sight impaired (SI) or severely sight impaired
(SSI) than the 1999 survey respondents. The two
samples did not differ in gender, whether one or both
eyes were affected by AMD or the time between diagno-
sis and survey completion.
Within the 2013 survey subgroups, respondents diag-
nosed after the 2009 RCOphth publication were
younger, less likely to be registered, less likely to have
both eyes affected by AMD and more likely to have been
ﬁrst diagnosed by an optometrist (table 2). Those diag-
nosed before the publication of the 2002 paper were
more likely to have dry AMD and less likely to have wet
AMD. Those diagnosed after the publication of the 2009
RCOphth guidelines were more likely to have wet AMD.
There were no differences in gender balance within the
2013 subgroups.
Experiences in the diagnostic consultation: 1999 versus
2013 samples
Respondents from the 2013 survey were signiﬁcantly
more likely than the 1999 respondents to report feeling
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that the HCP who diagnosed their condition was inter-
ested in them as a person (71% compared with 47% see
table 3). They were also more likely to report being
given the name of their condition at diagnosis (91% vs
78%) and being generally more satisﬁed with the diag-
nostic consultation (76% vs 61%).
Binary logistic regressions controlling for differences
in sociodemographic and eye-related factors, conﬁrmed
that being a 2013-survey respondent was a signiﬁcant
predictor of satisfaction with these aspects of healthcare
(see table 4 for odds ratios (ORs)).
Impact of 2002 publication of MDSQ results and 2009
RCOphth guidelines on healthcare experiences
Within the 2013 sample, a general pattern of increase in
information provision and satisfaction with the diagnos-
tic consultation was observed over the three time
periods studied (prepublication in 2002, between 2002
and 2009, and post-2009 RCOphth guidelines) for all
aspects of the consultation, apart from information pro-
vision on the likely progress of the macular condition
(see table 3). Unadjusted logistic regressions using the
‘year rank’ variable found an increasing trend in infor-
mation and support provision across time for six of the
ten aspects of healthcare experiences (see table 5).
Further unadjusted analyses using the 2013 survey sub-
groups found signiﬁcant increases in the same six
aspects of information and support provision after the
2002 paper publication compared with prepublication in
2002 (indicative of a combined effect of both interven-
tions). However, there were signiﬁcant improvements
made after the 2009 RCOphth guidelines publication
only for four aspects namely: information on the
Macular Society, provision of written information, receiv-
ing appropriate support, help or advice at the time of
diagnosis and overall satisfaction with the diagnostic
consultation.
Figure 2A–J shows the adjusted ORs for logistic regres-
sions controlling for the impact of sociodemographic,
eye-related and healthcare-related variables. In multivari-
able analyses, the trend for increasing satisfaction with
healthcare experiences across time remained signiﬁcant
for the following three aspects of healthcare: provision of
written information, information about the Macular
Society and being given appropriate support, help or
advice at the time of diagnosis. Once this trend was
adjusted for, of the 10 aspects of care, only overall satisfac-
tion with the diagnostic consultation signiﬁcantly
improved, and only after the 2009 RCOphth guidelines
publication. There were no signiﬁcant improvements
associated with the 2002 publication of the MDSQ results.
Women were less likely than men to report receiving
information and support on ﬁve aspects of care (see
ﬁgure 2A–J). Older respondents were more likely to
report overall satisfaction with the diagnostic consult-
ation and receiving appropriate help, support and
advice at diagnosis, but were less likely than younger
respondents to report receiving information on what to
do if they have a sudden deterioration in their vision.
Experiences with GPs around the time of diagnosis
Figures 3 and 4 show a comparison of the 1999 and
2013 survey responses on respondents’ views of GP
knowledge about AMD, and help and support received
from GPs in relation to their macular condition. In the
2013 survey, 163 respondents felt that their GP was ‘very
Table 1 Respondent characteristics in the 1999 and 2013 survey groups
Variables
1999 sample
(n=1187)
2013 sample
(n=1169)†
Statistic, p value, effect size
and n
Gender
Male 368 (31.0%) 358 (30.6%) χ2 (1)=0.04, p=0.84: n=2356
Female 819 (69.0%) 811 (69.4%)
Age at survey completion (years)
Mean (SD) 78.34 (7.10) 80.15 (7.99) t (2313.83)=−5.79, p<0.001***:
r=−0.02, n=2356Median 78.66 81.00
Registration status
Not registered 469 (39.5%) 790 (67.6%) χ2 (2)=206.53, p<0.001***:
Cramer’s V=0.30, n=2356Registered sight impaired (SI)/partially sighted 379 (31.9%) 256 (21.9%)
Registered severely sight impaired (SSI)/blind 339 (28.6%) 123 (10.5%)
Number of eyes affected
One eye 223 (18.8%) 226 (19.3%) χ2 (1)=0.11, p=0.74: n=2356
Both eyes 964 (81.2%) 943 (80.7%)
Years since diagnosis‡
Mean (SD) 5.91 (4.92) 5.55 (3.77) U=635, 839.00, z=0.30, p=0.77:
n=2249Median 5.00 5.00
Values are frequencies (valid percentage %) unless otherwise stated.
*p<0.05; **p<0.01; ***p<0.001.
†The majority of the 2013 survey respondents self-reported their ethnicity as ‘white’ (99.5%). No question on ethnicity was included in the
1999 survey.
‡For information. Not included in further analyses.
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well informed’ about their condition (23.8% of
responses). However, many more said that their GP was
‘not at all well informed’ (n=269, 39.3%). Additionally,
only 139 respondents (18.7%) reported that their GP
was ‘very helpful and supportive’ about their AMD, and
almost half of the survey respondents (47.8%) reported
that their GP was ‘not at all helpful/supportive’
(n=355).
Mann-Whitney tests found no signiﬁcant differences
between the 1999 and 2013 samples in reported GP
knowledge of AMD (U=321, 207.00, z=−0.67, p=0.50,
n=1641) but there was a signiﬁcant difference in reports
of GP supportiveness. Respondents from the 2013 survey
were more dissatisﬁed with the support provided by GPs
(U=314, 740.00, z=−7.66, p<0.001, n=1806).
DISCUSSION
Patient experiences are an important indicator of quality
of healthcare. This 2013 nationwide survey of people
with AMD found signiﬁcant improvements since a 1999
survey in patients being given the name of their macular
condition at diagnosis, feeling that the HCP who ﬁrst
diagnosed them was interested in them as a person and
overall satisfaction with the diagnostic consultation. Of
two interventions that might have inﬂuenced this
increase in satisfaction (the publication of the 1999
survey results and the 2009 publication of RCOphth
recommendations for information and support provision
to patients with AMD), only the latter was associated
with signiﬁcant improvements and this was only for
overall satisfaction with the diagnostic consultation.
Satisfaction with the three aspects of care measured in
both surveys was high initially, reducing the scope for
improvements which were nevertheless apparent over
time.
The 2013 survey included seven newly designed ques-
tions based on RCOphth recommendations for informa-
tion and support provision at diagnosis. Only three
recommendations showed a signiﬁcant trend of improve-
ment over time (for written information on the macular
condition, information on the Macular Society and for
receiving appropriate help, support and advice at diag-
nosis). However, there were no additional improvements,
over and above this general trend, following publication
of the 2009 guidelines. The proportion of respondents
reporting provision of this information and support
remains low. Additionally, the 2013 survey respondents
were more likely than the 1999 sample to report that
their GP had not been helpful and supportive about
their macular condition, and reported GP knowledge of
AMD remains low.
Table 2 Respondent characteristics in the 2013 survey subgroups
Variables
Before MDSQ
1999 paper results
publication ( July
2002) (n=194)
Between 2002
and 2009
(n=448)
After RCOphth
publication
(February 2009)
(n=476)
Statistic, p value: effect
size
Gender
Male 72 (37.1%) 135 (30.1%) 153 (32.1%) χ2 (2)=3.02, p=0.22
Female 122 (62.9%) 313 (69.9%) 323 (67.9%)
Age at survey completion (years)
Mean (SD) 82.12 (7.26) 80.56 (7.68) 79.37 (8.16) F (2, 1115)=8.86,
p<0.001***: ω2=0.01†Median 83.00 82.00 80.00
Registration status
Not registered 87 (44.8%) 269 (60.0%) 390 (81.9%) χ2 (4)=108.67, p<0.001***:
Cramer’s V=0.22Registered sight impaired (SI)/
partially sighted
62 (32.0%) 117 (26.1%) 67 (14.1%)
Registered severely sight impaired
(SSI)/blind
45 (23.2%) 62 (13.8%) 19 (4.0%)
Number of eyes affected
One eye 19 (9.8%) 61 (13.6%) 132 (27.7%) χ2 (2)=42.76, p<0.001***:
Cramer’s V=0.20Both eyes 175 (90.2%) 387 (86.4%) 344 (72.3%)
Wet AMD only v dry AMD only v mixed wet and dry AMD
Wet AMD only 43 (22.2%) 175 (39.1%) 195 (41.0%) χ2 (4)=26.22, p<0.001***:
Cramer’s V=0.11Dry AMD only 108 (55.7%) 176 (39.3%) 201 (42.2%)
Wet and dry AMD 43 (22.2%) 97 (21.7%) 80 (16.8%)
HCP who first diagnosed AMD
Hospital eye specialist 131 (67.5%) 258 (57.6%) 230 (48.3%) χ2 (2)=22.07, p<0.001***:
Cramer’s V=0.14Optometrist 63 (32.5%) 190 (42.4%) 246 (51.7%)
Values are frequencies (valid percentage %) unless otherwise stated.
*p<0.05, **p<0.01, ***p<0.001.
†ω2=0.01 represents a small effect size, 0.06 a medium effect size and 0.14 a large effect size.
AMD, age-related macular degeneration; HCP, healthcare professional; MDSQ, Macular Disease Society Questionnaire; RCOphth, Royal
College of Ophthalmologists.
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Table 3 Comparison of responses to questions on experiences within the diagnostic consultation across survey sample groups
1999 survey
sample
2013 survey
sample
χ2, p value: effect
size and n
2013 survey sample subgroups
χ2, p value:
effect size
and n
Before MDSQ 1999
paper results
publication
( July 2002)
Between 2002
and 2009
After RCOphth
guidelines
publication
(February 2009)
Interested in you as a person?† 537 (46.9%) 805 (71.2%) χ2 (1)=138.58,
p<0.001***:
ϕ=0.25,
n=2276
126 (67.0%) 302 (70.1%) 351 (74.8%) χ2 (2)=4.86,
p=0.09:
n=1088
Given the name of your condition?‡ 906 (77.6%) 1045 (91.0%) χ2 (1)=78.34,
p<0.001***: ϕ=0.18,
n=2315
165 (86.4%) 401 (91.1%) 435 (92.6%) χ2 (2)=6.30,
p=0.04*:
Cramer’s
V=0.08,
n=1101
Generally satisfied with diagnostic
consultation?§
698 (61.0%) 856 (75.8%) χ2 (1)=57.59,
p<0.001***:
ϕ=0.16,
n=2273
129 (70.1%) 320 (73.7%) 382 (82.0%) χ2 (2)=13.85,
p=0.01*:
Cramer’s
V=0.11,
n=1084
Given written information?¶ – – – 34 (17.7%) 133 (30.4%) 193 (41.9%) χ2 (2)=37.98,
p<0.001***:
Cramer’s
V=0.19,
n=1090
Given appropriate support, help
or advice?††
– – – 86 (45.7%) 229 (52.2%) 302 (64.1%) χ2 (2)=23.25,
p<0.001***:
Cramer’s
V=0.15,
n=1098
Information about the Macular Society?‡‡ – – – 28 (15.1%) 106 (24.0%) 150 (31.9%) χ2 (2)=21.07,
p<0.001***:
Cramer’s
V=0.14,
n=1097
Information on action if sudden
deterioration in your vision?§§
– – – 80 (42.3%) 227 (51.4%) 262 (56.3%) χ2 (2)=10.67,
p=0.005**:
Cramer’s
V=0.10,
n=1096
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Table 3 Continued
1999 survey
sample
2013 survey
sample
χ2, p value: effect
size and n
2013 survey sample subgroups
χ2, p value:
effect size
and n
Before MDSQ 1999
paper results
publication
( July 2002)
Between 2002
and 2009
After RCOphth
guidelines
publication
(February 2009)
Given information about likely progress of
macular condition?¶¶
– – – 84 (43.5%) 203 (46.2%) 190 (40.6%) χ2 (2)=2.94,
p=0.23:
n=1100
Other contacts for help and support?††† – – – 29 (15.4%) 75 (17.1%) 90 (19.5%) χ2 (2)=1.75,
p=0.42:
n=1088
Told about visual hallucinations?‡‡‡ – – – 26 (13.5%) 66 (15.4%) 80 (17.2%) χ2 (2)=1.47,
p=0.48:
n=1085
Values are frequencies of ‘yes’ responses (valid percentage %) unless otherwise stated.
*p<0.05; **p<0.01; ***p<0.001.
†“Did you feel that this healthcare professional (who first diagnosed your macular condition), was interested in you as a person?” (Response ‘Yes’ or ‘No’ here and to all questions listed below).
‡“Were you given the name of your condition at the time of diagnosis?” (This question was included in the MDSQ 1999 but the responses were not reported in the 2002 paper).
§“Overall, did you feel that the diagnostic consultation with this healthcare professional was satisfactory?”
¶“Were you given any written information about your macular condition at the time of diagnosis?”
††“Do you feel you were given appropriate support, help or advice at the time of diagnosis?”
‡‡“Were you given information about the Macular Society (or the Macular Disease Society, as it was previously called) at the time of diagnosis?”
§§“Were you given any information around the time of diagnosis about what to do if you were to have a sudden deterioration in your vision?”
¶¶“Around the time of diagnosis, were you given information about the likely progress of your macular condition?”
†††“Were you given any other contacts for help and support at the time of diagnosis?”
‡‡‡“Were you told by a healthcare professional, around the time of diagnosis, of the possibility of experiencing visual hallucinations as a side effect of sight loss?”
MDSQ, Macular Disease Society Questionnaire; RCOphth, Royal College of Ophthalmologists.
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Table 4 Predictors of healthcare experiences in comparable questions from the 1999 and 2013 surveys; unadjusted (univariable analyses) and multivariable analysis
adjusting for all other predictors
Predictor
Interested in you as a person?†
(n=2276) Given name of condition?‡ (n=2315) Overall satisfaction?§ (n=2273)
Unadjusted OR
(95% CI)
Adjusted OR
(95% CI)
Unadjusted OR
(95% CI)
Adjusted OR
(95% CI)
Unadjusted OR
(95% CI)
Adjusted OR
(95% CI)
Sample (1999 or 2013)
1999 1.00 1.00 1.00 1.00 1.00 1.00
2013 2.80 (2.35 to 3.33)*** 2.75 (2.28 to 3.31)*** 2.92 (2.29 to 3.73)*** 2.78 (2.14 to 3.61)*** 2.00 (1.67 to 2.40)*** 1.90 (1.56 to 2.31)***
Gender
Male 1.00 1.00 1.00 1.00 1.00 1.00
Female 0.73 (0.61 to 0.87)** 0.71 (0.59 to 0.86)*** 0.80 (0.63 to 1.03) 0.77 (0.60 to 1.00)* 0.68 (0.55 to 0.82)*** 0.67 (0.55 to 0.82)***
Age at survey completion¶ 1.02 (1.01 to 1.03)** 1.01 (1.00 to 1.02) 0.99 (0.97 to 1.00) 0.98 (0.97 to 1.00)* 1.03 (1.01 to 1.04)*** 1.02 (1.01 to 1.04)***
Registration status
Contrast 1
Not registered 1.00 1.00 1.00 1.00 1.00 1.00
Registered as SI or SSI 0.50 (0.36 to 0.70)*** 0.95 (0.64 to 1.42) 0.30 (0.19 to 0.47)*** 0.60 (0.36 to 1.02) 0.62 (0.44 to 0.89)** 0.89 (0.59 to 1.35)
Contrast 2
Registered SI 1.00 1.00 1.00 1.00 1.00 1.00
Registered as SSI 0.87 (0.68 to 1.10) 0.97 (0.75 to 1.25) 0.65 (0.48 to 0.88)** 0.72 (0.53 to 0.97)* 0.70 (0.55 to 0.91)** 0.74 (0.57 to 0.96)
Number of eyes affected
One eye affected 1.00 1.00 1.00 1.00 1.00 1.00
Both eyes affected 0.78 (0.63 to 0.97)* 0.77 (0.60 to 0.97)* 0.78 (0.58 to 1.06) 0.92 (0.66 to 1.28) 0.78 (0.62 to 0.99)* 0.74 (0.58 to 0.96)*
Adjusted model statistics – χ2 (6)=160.91,
p<0.001***
– χ2 (6)=100.80,
p<0.001***
– χ2(6)=97.05,
p<0.001***
Adjusted model Nagelkerke’s R2†† – 0.09 – 0.07 – 0.06
*p<0.05, **p<0.01, ***p<0.001
†“Did you feel that this healthcare professional (who first diagnosed your macular condition), was interested in you as a person?” (Response was yes =1, no =0 for this and all questions below.)
‡“Were you given the name of your condition at the time of diagnosis?”
§“Overall, did you feel that the diagnostic consultation with this healthcare professional was satisfactory?”
¶In logistic regression, for continuous variables such as age at survey completion, an OR over 1 indicates increasing likelihood of the outcome as the predictor increases (ie, as age increases).
††Nagelkerke’s R2 is a measure of model fit, where 0 indicates the predictors poorly predict the outcome and 1 is where the model predicts the outcome perfectly.
SI, sight impaired; SSI, severely sight impaired.
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Table 5 Unadjusted ORs from binary logistic regressions investigating changes in information and support provision since the 2002 publication of the 1999 survey results and the 2009 RCOphth guidelines
Interest as a
person?
OR (95% CI)
n=1088
Overall
satisfaction?
OR (95% CI)
n=1084
Name of condition?
OR (95% CI)
n=1101
Written information?
OR (95% CI)
n=1090
Info on
deterioration?
OR (95% CI)
n=1096
Help and support?
OR (95% CI)
n=1098
Macular Society
contact?
OR (95% CI)
n=1097
Other contacts?
OR (95% CI)
n=1088
Likely progress?
OR (95% CI)
n=1100
Hallucination?
OR (95% CI)
n=1085
Sociodemographic
Gender
Male 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Female 0.73 (0.54 to 0.97)* 0.67 (0.49 to 0.91)* 0.99 (0.64 to 1.54) 0.79 (0.60 to 1.03) 0.78 (0.61 to 1.01) 0.68 (0.52 to 0.88)** 1.05 (0.79 to 1.40) 0.90 (0.65 to 1.25) 0.63 (0.49 to 0.81)*** 0.98 (0.70 to 1.39)
Age at survey
completion‡
1.01 (1.00 to 1.03) 1.03 (1.01 to 1.05)** 0.96 (0.93 to 0.98)** 0.98 (0.96 to 0.99)** 0.97 (0.95 to 0.98)*** 1.01 (1.00 to 1.03) 0.99 (0.97 to 1.01) 1.01 (0.99 to 1.03) 1.00 (0.99 to 1.02) 1.03 (1.00 to 1.05)*
Eye-related variables
Number of eyes affected
One eye 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Both eyes 0.58 (0.40 to 0.83)** 0.57 (0.38 to 0.85)** 0.87 (0.50 to 1.50) 0.60 (0.44 to 0.81)** 0.77 (0.57 to 1.04) 0.58 (0.42 to 0.80)** 0.55 (0.40 to 0.75)*** 0.93 (0.63 to 1.38) 0.82 (0.61 to 1.11) 0.89 (0.60 to 1.33)
Registration status
Contrast 1
Not registered 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Registered as SI
or SSI
0.52 (0.30 to 0.92)* 0.65 (0.36 to 1.19) 0.16 (0.07 to 0.38)*** 0.58 (0.33 to 1.02) 0.29 (0.17 to 0.49)*** 0.31 (0.18 to 0.53)*** 0.89 (0.49 to 1.62) 4.13 (2.16 to 7.91)*** 0.82 (0.48 to 1.38) 2.92 (1.14 to 4.61)*
Contrast 2
Registered as SI 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Registered as SSI 1.11 (0.69 to 1.76) 0.63 (0.38 to 1.03) 0.48 (0.26 to 0.87)* 0.86 (0.53 to 1.40) 0.93 (0.60 to 1.44) 0.55 (0.35 to 0.85)** 1.15 (0.70 to 1.90) 1.11 (0.67 to 1.83) 1.05 (0.68 to 1.63) 0.82 (0.47 to 1.44)
Wet or dry AMD
Contrast 1
Wet AMD only
and mixed wet
and dry AMD
1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Dry AMD only 0.44 (0.26 to 0.75)** 0.48 (0.27 to 0.84)* 2.27 (0.94 to 5.51) 0.59 (0.35 to 1.01) 0.57 (0.35 to 0.92)* 0.29 (0.17 to 0.47)*** 0.65 (0.37 to 1.15) 0.67 (0.35 to 1.28) 0.59 (0.36 to 0.97)* 0.44 (0.22 to 0.89)*
Contrast 2
Wet AMD only 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Mixed wet and dry
AMD
0.67 (0.46 to 0.98)* 0.60 (0.40 to 0.90)* 1.17 (0.68 to 2.03) 0.76 (0.54 to 1.09) 0.82 (0.59 to 1.14) 0.62 (0.44 to 0.87)** 0.84 (0.58 to 1.22) 0.85 (0.56 to 1.31) 0.98 (0.71 to 1.37) 0.88 (0.57 to 1.36)
Healthcare-related variables
HCP who first diagnosed
Hospital eye
specialist
1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 n/a§
Optometrist 2.49 (1.88 to 3.30)*** 2.40 (1.77 to 3.26)*** 0.63 (0.42 to 0.96)* 0.73 (0.57 to 0.95)* 0.86 (0.68 to 1.10) 1.28 (1.01 to 1.63)* 0.94 (0.71 to 1.23) 0.91 (0.67 to 1.25) 1.11 (0.88 to 1.42) n/a§
Year of diagnosis
(rank)‡
1.02 (1.00 to 1.05) 1.03 (1.01 to 1.06)* 1.06 (1.03 to 1.10)** 1.10 (1.07 to 1.14)*** 1.04 (1.02 to 1.07)*** 1.07 (1.04 to 1.09)*** 1.08 (1.05 to 1.11)*** 1.02 (0.98 to 1.05) 0.99 (0.97 to 1.01) 1.02 (0.99 to 1.06)
Survey time group
Contrast 1
Before July 2002
publication of
MDSQ 1999
results
1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
After the 2002
publication
(combined
intervention effect)
1.58 (0.80 to 3.14) 2.24 (1.10 to 4.59)* 3.47 (1.33 to 9.02)* 7.31 (3.25 to 16.42)*** 2.58 (1.36 to 4.91)** 2.84 (1.50 to 5.38)** 4.74 (1.99 to 11.29)*** 1.37 (0.58 to 3.25) 0.96 (0.51 to 1.81) 1.41 (0.57 to 3.48)
Continued
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This is the ﬁrst large-scale survey to examine whether
improvements in practice followed interventions
designed to improve experiences of patients with AMD
in the healthcare system. The survey is also unique in
examining whether respondents felt they were receiving
adequate support from their GPs for AMD. We have
included several important sociodemographic, eye-
related and healthcare factors linked to patients’
experiences in the multivariable analyses (table 4 and
ﬁgure 2A–J). Of particular note is the association
between registration as SI or SSI and lack of information
provision at diagnosis on what patients need to do if
they experience a sudden deterioration in vision. This
ﬁnding suggests that lack of this information may cause
subsequent sight loss sufﬁcient to warrant registration.
Respondents who were registered were also more likely
to report not being given the name of their macular
condition nor receiving appropriate help, support and
advice in the diagnostic consultation. Respondents with
dry AMD were less likely than those with wet AMD to be
given information at diagnosis on what to do if they
experience a sudden deterioration in vision. This is
despite our current knowledge that if dry AMD turns to
wet AMD, it is important that patients should seek help
quickly as treatment is available that may prevent
unnecessary sight loss.
Previous research has consistently found that older
patients tend to be more satisﬁed with their healthcare
experiences.19–21 There is some evidence also of women
being less satisﬁed than men albeit a less consistent rela-
tionship.20 22 23 Our results show some similar ﬁndings
and some differences. In this study, we were unable to
establish whether differences in reported information
and support provision were due to differences in patient
characteristics (eg, expectations and recall) or differen-
tial treatment from HCPs providing less information and
support to women than men, and less information but
more help, support and advice to older people than
younger people. Nevertheless, an awareness of these dif-
ferences should prompt HCPs to check these particular
‘at risk’ groups have received and understood important
information.
The response rate to the 2013 survey was low, but was
not dissimilar to that of other surveys including the last
nationwide General Practice Patient Survey (35.7% for
2015)24 and the Macular Society’s survey the previous
year.17 One might question the representativeness of our
survey sample. Individuals may have joined the Macular
Society because they had unsatisfactory experiences in
their diagnostic consultations and sought information
and support elsewhere. Conversely, this sample may have
received information about the Macular Society in the
diagnostic consultation more often than the general
AMD population and thus be more satisﬁed. Members
may have higher expectations of information and
support than the general AMD population and be more
likely to request information at diagnosis, if it is not
offered. There has yet to be a large, geographically
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Figure 2 (A–J) Adjusted ORs for binary logistic regressions of satisfaction with healthcare experiences.
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representative population study of AMD in the UK, so
we are currently unable to estimate the representative-
ness of our sample. Additionally, no sociodemographic
information was available on the non-responders to the
survey to help estimate the representativeness of
the ﬁnal sample. As the most common reason stated by
the ‘non-responders’ who returned paperwork was ‘old
age’, followed by ‘ill health’, it was possible that those
younger and in better general health were over-
represented in our survey. However, the 2013 sample was
Figure 2 Continued
Figure 3 Comparison of the
1999 and 2013 survey responses
to the question “Around the time
you were first diagnosed with your
macular condition, to what extent
was your GP well-informed about
your condition?”a
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on average older than the 1999 sample, and thus there
seems not to be an over-representation of younger
people in this sample. In comparison, non-responders to
the 1999 survey cited ‘ill health’ or ‘visual impairment’
as the most common reasons for non-response. There
were signiﬁcantly fewer respondents registered as SI/SSI
in the 2013 sample compared with the 1999 sample.
Consequently, registration status was controlled for in
the analyses in this report.
Respondents were asked to reﬂect on their experi-
ences at diagnosis and this may be subject to recall bias.
The use of survey methodology retrospectively to investi-
gate patient experiences in consultations has been previ-
ously reported.25 Being diagnosed with a condition that
could lead to sight loss is, in our experience of subse-
quent in-depth interviews with a subsample of respon-
dents, a particularly memorable event for most people.
The literature on autobiographical memory suggests that
women recall more details than men.26 In this study,
however, men were more likely to report receiving
several aspects of information and support provision
than women. This suggests that recall bias was not the
main problem here but rather women may have
received less information and support than men. The
information that patients recall from their diagnostic
consultation, even if asked years later, may still be rele-
vant and important particularly for AMD where only a
minority of patients are seen regularly—those receiving,
or being monitored for treatment.
It is important to note that the results reported here
demonstrate changes in information and support provi-
sion that occurred around the time of the interventions:
we are not able to demonstrate direct cause and effect.
The inclusion of the questions on experiences with GPs
(who are unlikely to have read the RCOphth guidelines)
could be seen to act as a control to test whether patient
experiences would have improved across time regardless
of the RCOphth guidelines. The lack of improvement in
reports of experiences with GPs lends weight to the view
that the RCOphth guidelines may well have had a posi-
tive inﬂuence on eye-care professionals which in turn
may have improved overall patient satisfaction with the
diagnostic consultation.
It will be important to investigate HCPs’ responses
and explanations for the ﬁndings reported here.
Perhaps the introduction of anti-VEGF injections for wet
AMD has meant eye specialists are hard-pushed to ﬁnd
the time to provide adequate information and support
in their diagnostic consultations? Perhaps eye-care pro-
fessionals do not currently feel conﬁdent in providing
the information recommended, for example, on the
likely progress of macular conditions? Rates of diagnosis
of AMD are expected to increase in the future, putting
more pressure on eye clinics. High-quality written infor-
mation for people with AMD, pertinent to the RCOphth
guidelines, is provided to eye clinics free of charge by
the Macular Society, but appears to be underused. (See
https://www.macularsociety.org/resources for a list of
resources.) This information might usefully be provided
in community and primary care settings. Indeed our
results indicate that 45% of respondents considered that
it was their optometrist who ﬁrst diagnosed their AMD,
and many reported seeing their GP about their macular
condition. It will be important to determine what obsta-
cles are preventing the provision of written information
to patients with AMD, and then take appropriate action
to improve access to written material that is acceptable
to patients and HCPs, and to monitor its impact.
Previous research27 published in 2013 recommended a
patient-centred approach to providing information
about AMD. However, progress to date seems limited.
Empathetic handling of the diagnosis, and support from
HCPs is a priority27 and our results show that there is
room for improvement.
Our ﬁndings suggest that, for people with AMD, infor-
mation and support provision is low at diagnostic consulta-
tions with eye-care professionals and in GP consultations.
There is a major opportunity here to improve patient
experiences using an available patient information booklet
at no expense to the health service. (See https://www.
macularsociety.org/sites/default/ﬁles/resource/Macular
%20Society%20Guide%20to%20AMD%202016_0.pdf).
Figure 4 Comparison of the
1999 and 2013 survey responses
to the question “To what extent
has your GP been helpful and
supportive about your macular
condition?”a
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The expected beneﬁts would be nationwide for the
rising population of older people at risk of AMD.
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